Directions for Medical Decision Making
With no little apprehension and a great deal of anticipation I accepted the appointment to the editorship of Medical Decision Making. I am indebted to Lee Lusted and to Dennis Fr~back for most of rny education in the theory and practice of editing, although Lock's A DijTicult Balance: Editorial Peer Review in Medicine 1 was also helpful. But my appreciation of Lee and Dennis extends beyond the mechanics of journal editing. Lee guided MDM through its difficult formative years, and solicited for the fledgling journal several papers that are widely quoted in the field. Dennis took the helm during a problematic transition in publishers, established an excellent relationship with the new group, Hanley and Belfus, and rebuilt the trust in the journal. I reap where they've planted and tended; the manuscript flow is sufficient and the journal's reputation is sound. Both men are patient with authors and reviewers, and have taken an active role in revising many papers that ultimately have been published in MDM. I pledge similar efforts for the new editorial group.
Robert M. Centor, MD, Jay J. J. Christensen-Szalanski, PhD, MPH, and Stephen G. Pauker, MD, have agreed to serve as associate editors for the next three years.
They will be working on special projects and providing special expertise in some of the scholarly interests represented in the journal. Bob Centor will assist in recruiting clinical articles, a mainstay of the journal. Jay Christensen-Szalanski, who has served with great distinction as Book Review Editor, will continue his yeoman service in compiling the &dquo;Recent Developments...&dquo; section, and will help select and manage papers dealing with the cognitive aspects of decision science. Steve Pauker will continue to edit the Clinical Decision Conference, one of MDM's main attractions since its inauguration in 1981.
My priorities for MDM reflect the directions of the scientific field and the Society for Medical Decision Making, as well as some personal desires for the development of scholarship in decision making. Foremost, we must see applications of decision making techniques in clinical medicine. Such papers will have the greatest impact on readership, citations to the journal, and membership in the Society. I urge readers active in the clinical arena to increase submissions of clinical decision analyses, clinical prediction rules, and related manuscripts.
In the 1990s extensions of medical decision making to health care management and outcome assessment will come increasingly into the limelight. Donald Berwick's 1987 Presidential Address included a call to work in this important area. I plan to solicit reports actively in this field; the readership and authors of MDM have significant contributions to make in sharpening the analytic focus of health care management. I see a third growth area in medical informatics. The Long Range Planning Panel on Medical Informatics of the National Library of Medicine, chaired by Ted Shortliffe in 1986, had several members who were active contributors to (and editors of ) MDM. I see the scientific content of medical informatics and medical decision making as overlapping Venn Diagrams, with a substantial degree of commonality. Already several papers on applications of artificial intelligence have appeared in the journal; I shall solicit articles that concern the clinical or decision making aspects of medical computer science. MDM will continue to be a principal repository for technical or methodologic articles on medical decision making. As I have observed the flow of manuscripts over the last three years, I see no letup in this area. However, the journal must broaden its base if it is to continue to grow. I encourage potential authors and reviewers to contact the journal or editorial office; let us work together to see substantial and significant growth in MDM. 
J. ROBERT BECK, MD

Editor-in-Chief
Prevention Trials
In recent years, clinical decision making has been expanded to involve the choice and design of clinical trials.1.2 Whether or not to conduct certain trials, as well as size and duration of trials, have been placed in decision making models. The article by Baker and Heidenberger' in this issue, which extends previous models, should be of particular interest to MDM readers because of its focus on prevention trials and the large degree of clinical input required by these models.
Two aspects of prevention trials particularly important in a decision making paradigm are their size and their usually lengthy duration. Relative to classic therapeutic clinical trials, prevention trials appear enormous in sample size as well as overall complexity. The complexity is increased by many factors, especially when prevention trials are conducted as multicenter efforts, each with a separate administrative and scientific infrastructure. Because of their size and duration, prevention trials can consume a large proportion of a budget-even a large federal agency budget. In addition, prevention trials require long-term planning and even longer-term support. So these types of trials must be chosen carefully and their designs streamlined to ensure a high probability of a definitive test of the primary hypotheses of interest. For these reasons alone, efforts such as those of Baker and Heidenberger are crucial; of course, efforts by federal agencies to use such approaches are required, as well. But federal agencies usually follow the recommendations of extramural scientific experts, who must judge the worth of each scientific endeavor or proposal against some often-arbitrary standard. Unless these scientists are willing to undertake the time and effort necessary to understand and use complex decision models such as the one presented, decisions about funding major prevention trials will continue to be an unsystematic process that probably does not maximize the potential benefits of the nation's research investment.
The analysis of prevention trials affords another lesson, borrowed from attributable risk calculations in epidemiology: large trials can be desirable because of potentially large benefits from a trial demonstrating a small effect, and small and/or inexpensive trials may be desirable even if the benefit is not too likely. But readers and decision analysts must be cautioned: despite the findings of a model suggesting the funding of a small trial, investigators (and review committees) will be wary of extensive involvement in trials with low power or a small probability of success. The scientific payoff implicit in choosing trials on which to spend one's too-precious time is not included in these models, and a good cost-effectiveness ratio will not be sufficient to persuade talented investigators. Another caution is related to the readiness of a specific field for the sophisticated analyses suggested by Baker and Heidenberger. Few areas of health promotion and disease prevention are mature enough at this time to have a sufficient repository of studies ready for fielding to provide a true test of these models. In the specific case of cancer prevention studies, outcomes are not planned to result in immediate recommendations for clinical or public health action. Their research products are not measured on the same scale as possibly competing studies, making the objective of the decision making model more complex. Possibly, wise scientists and clinicians might be able to estimate the worth of each study on some common scale, or models to optimize multiple attributes can be developed, but these are likely to be very difficult additional tasks.
Those readers of MDM who might find the mathematical manipulations of the paper a bit difficult should nevertheless spend a few moments with the excellent example showing these models applied to trials in colorectal screening. Notice the large number of assumptions or prior estimates requiring expert input: clinical hazards and side effects of the experimental (prevention) regimen; acceptability of the regimen related to possible results of the trial and the cost of the regimen; likelihood of adoption of the procedure with and without the trial; the potential efficacy of the regimen ; and the cost and effectiveness of the &dquo;next best&dquo; health intervention. Many of these quantities are unobservable prior to the trial, and it is mandatory for agencies funding prevention trials to involve skilled clinicians, especially those who think in terms of populations of patients and decision making, in the panels and groups who ultimately decide the features of large prevention trials. Despite the difficulty of obtaining and using expert information, clinical input is essential.
